Released June 11, 2021 | BEIJING
en
Researched by Industrial Info Resources (Sugar Land, Texas)--Key players in the Chinese contract development and manufacturing organization (CDMO) market such as Wuxi AppTec & Wuxi Biologics, Asymchem Laboratories (Tianjin) Company, Ltd., Porton Pharma Solutions Ltd., Apeloa Pharmaceutical Company, Ltd and Zhejiang Jiuzhou Pharmaceutical Company Ltd, among others, have employed various strategies to expand their product and application offerings and global footprint, and augment their market share.
For now, the overall industry concentration of the Chinese CDMO industry is low, at less than 25%. Industry concentration represents the percentage of market share owned by the largest firms in the industry.
However, over time, the transfer of overseas production capacity has accelerated, the development of Chinese pharmaceutical innovation and progress in research and development have continued, and CDMO companies' own technical strength has improved. China's CDMO industry concentration is expected to increase in the next few years.
Industrial Info is tracking eight active CDMO projects in China, worth almost $605 million. Ruibo Pharmatech Company Ltd features the largest expenditure on CDMO construction, with more than $230 million.
Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of projects.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
For now, the overall industry concentration of the Chinese CDMO industry is low, at less than 25%. Industry concentration represents the percentage of market share owned by the largest firms in the industry.
However, over time, the transfer of overseas production capacity has accelerated, the development of Chinese pharmaceutical innovation and progress in research and development have continued, and CDMO companies' own technical strength has improved. China's CDMO industry concentration is expected to increase in the next few years.
Industrial Info is tracking eight active CDMO projects in China, worth almost $605 million. Ruibo Pharmatech Company Ltd features the largest expenditure on CDMO construction, with more than $230 million.
Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a list of projects.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
